$103.40▼ 3.61 (3.37%)
Real-time prices · US Markets88% of 24 covering analysts have a positive rating.
low return on equity (-27%).
Quality
2.1
Health
8.2
Growth
6.1
Valuation
5
Sentiment
8.4
Analyst Target
$127.18
▲ +23.0% from current
Price Chart
Latest News
- Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More
- Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-23.7×
next 12 months est.
Market Cap
$8.5B
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-27.1%
return on equity
Beta
1.96
vs S&P 500
52-Week Range
$37 — $130
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Kymera Therapeutics, Inc. right now?
Kymera Therapeutics, Inc.'s Q·Score is 5.6/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. 88% of 24 covering analysts have a positive rating. Key area to monitor: low return on equity (-27%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for KYMR?
The consensus price target for KYMR is $127.18, based on ratings from 22 Wall Street analysts. This is 23.0% above the current price of $103.40. Price targets are forward-looking estimates and not guarantees of future performance.
Is KYMR overvalued or undervalued?
Kymera Therapeutics, Inc. (KYMR) scores in line with sector averages on valuation metrics. The consensus analyst price target of $127.18 is 23% above the current price.
When does Kymera Therapeutics, Inc. report its next earnings?
Kymera Therapeutics, Inc. is scheduled to report earnings in 4 days, on August 5, 2026.
What is Kymera Therapeutics, Inc.'s profit margin?
Kymera Therapeutics, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
Is Kymera Therapeutics, Inc.'s revenue growing?
Kymera Therapeutics, Inc. is reporting strong year-over-year growth of 55.5%.
How much debt does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has a debt-to-equity ratio of 0.05×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 10.81×, indicating comfortable short-term liquidity.